Retatrutide vs Tirzepatide: Bigger Promise, or Better Right Now?

Here's your clearest answer: tirzepatide remains the better real-world choice. It carries FDA approval, a settled weekly escalation protocol, and a straightforward decision path. Retatrutide has genuine upside potential, but it's still investigational and not yet available for use.

Your starting point: tirzepatide now

Tirzepatide wins decisively on usability and access. It's FDA-approved as Zepbound, fully calibrated for weekly dosing, and straightforward to personalize against your tolerance and budget. Retatrutide might eventually show a higher ceiling, but Lilly hasn't approved it yet—it's still completing Phase 3 as of March 2026. To dig into what tirzepatide actually feels like, read tirzepatide weight loss and tirzepatide side effects.

• Choose tirzepatide if you want to start now with FDA approval, clear dosing, and predictable outcomes.
• Watch retatrutide if you're optimizing for ceiling potential and can wait for Phase 3 completion and regulatory clearance.
• Skip the temptation to treat their numbers as directly comparable—these are separate trials, not a head-to-head matchup yet.

Retatrutide's bigger ceiling: what the Phase 3 data shows

Retatrutide genuinely looks bigger because the numbers actually are bigger. Its published Phase 2 trial showed mean weight reduction up to 24.2% at 48 weeks, and Lilly's December 11, 2025 Phase 3 TRIUMPH-4 topline delivered 28.7% average weight loss at 68 weeks in adults with obesity plus knee osteoarthritis. Lilly confirms the compound has completed two Phase 3 trials, but it still lacks FDA approval and public access as of March 2026.

Why tirzepatide is the easier call right now

Tirzepatide has what retatrutide doesn't yet: a proven prescribing bridge from trial evidence to real-world use. The FDA label is crystal clear—Zepbound is approved for chronic weight management with a straightforward weekly escalation: 2.5 mg start, then maintenance at 5 mg, 10 mg, or 15 mg per FDA labeling. The label's 72-week obesity data shows the 15 mg dose achieved 20.9% mean weight reduction, with 56.7% of participants hitting 20% or greater weight loss. You can also benchmark it directly against other approved options like semaglutide injection.

• Tirzepatide wins on approval, prescription clarity, and a direct evidence-to-practice pathway right now.
• Retatrutide wins on ceiling potential: triple-agonist biology and bigger topline numbers, but no label yet.
• Both are once-weekly, so your real decision is timing: do you want the settled choice now, or are you willing to wait for potentially higher ceiling?

Your decision: timeline versus ceiling

If you want a realistic near-term option, tirzepatide is your anchor. SURMOUNT-1 is complete and its record stays actively updated through July 24, 2025, whereas retatrutide's obesity program is still maturing—TRIUMPH-1 is ongoing with expected completion around April 2026. The real gap: tirzepatide is already in the post-approval phase, collecting real-world evidence. Retatrutide is still gathering Phase 3 data before seeking FDA review.

Which one fits your situation?

Retatrutide is your watchlist name if you're optimizing for absolute ceiling—the question 'what could eventually go highest?' Tirzepatide is the smarter choice if you're asking 'what's strongest, safest to evaluate, and usable right now?' Higher upside potential doesn't mean better today. That distinction is exactly why tirzepatide remains the clearer choice in May 2026.